Pharma
Pharma Sales Force Excellence Analytics
Pharma sales analytics breaks when CRM coverage reports, IMS or internal Rx, and finance invoicing refresh on different calendars. Mr coverage analysis looks strong on visit counts while high-potential doctors stay under-called because lists and segments disagree. Territory attainment pharma turns into arguments when quotas ignore seasonality, tender timing, or stockist service gaps that no MR can detail away. Doctor prescription trend signals arrive after competitive detail and access shifts already landed. New product adoption pharma fragments across sample trackers, early Rx files, and distributor push without one adoption curve per patch.
FireAI joins call and route data, prescription or proxy feeds you approve, territory targets, and launch milestones so pharma sales analytics answers whether MRs cover the right doctors at the right frequency, how zones track to fair attainment with explained variance, which prescribers moved on molecule share with leading indicators, and where new product adoption pharma leads or lags with stockist and activity context.
The domain covers MR coverage and visit frequency analysis, zone and territory attainment tracking, doctor-wise prescription trend analysis, and new product adoption by territory, through chat, dashboards, and causal chains field and brand leaders can act on in the same review cycle. See how it works: get a demo.
MR coverage and visit frequency analysis
Mr coverage analysis fails when the system counts any check-in as a quality visit while high-write doctors see gaps between planned and actual detailing. Visit frequency without potential weighting rewards busywork on easy accounts and hides under-coverage where share is still winnable.
FireAI aligns MR beats to doctor or outlet master, overlays Rx or proxy potential bands where data exists, and scores coverage as reach versus agreed norms by segment. Mr coverage analysis highlights double coverage, true whitespace, and routes where frequency is high but message or sample compliance lags.
How FireAI solves the problem: It reconciles planned versus actual calls with effective dates, flags doctors who crossed segment thresholds without a plan update, and surfaces MR pairs or overlaps that distort fair workload views.
What FireAI tracks:
- Coverage rate versus segment norm by MR and patch
- Visit frequency distribution for high and medium potential lists
- Gap days and route exceptions versus beat policy
- Co-detail and MSL touch correlation where joint calls log separately
First-line managers use mr coverage analysis inside pharma sales analytics to rebalance beats before month-end recovery drives burn out the field.
MR coverage pulse
Zone and territory attainment tracking
Territory attainment pharma stalls when targets mix rupees, units, and molecule weights without a single attainment logic the field trusts. Zones look green on invoice while Rx or secondary says share leaked in the same period.
FireAI harmonizes quota components you define, layers Rx or sell-out where available, and shows attainment with mix and timing bridges. Territory attainment pharma exposes patches where primary over-ships mask soft demand and regions where ethical execution is strong but tender timing depressed the score.
How FireAI solves the problem: It locks target versions to dates, attributes variance to price, volume, mix, and timing buckets, and flags territories where attainment and coverage trends diverge enough to warrant a plan review.
What FireAI tracks:
- Attainment to target by zone, region, and MR roll-up
- Primary versus proxy demand divergence by territory
- Launch and mature SKU contribution to attainment
- Historical seasonality-adjusted expected run rate
Zonal managers use territory attainment pharma with pharma sales analytics to coach with numbers that match what reps experience in the market.
Ask FireAI about attainment
See how your team can ask questions in plain language and get instant analytics answers.
Doctor-wise prescription trend analysis
Doctor prescription trend reporting is often a static rank that hides whether share rose on patient mix, access, or competitive pressure. Without linkage to activity and stockist service, sales blames marketing and marketing blames the field.
FireAI time-series prescription or proxy share by doctor with confidence labels, joins recent detailing and samples, and highlights inflection weeks. Doctor prescription trend analysis surfaces prescribers who moved bands, stalled after a strong start, or diverged from peer clusters in the same specialty.
How FireAI solves the problem: It detects trend breaks against control groups, suggests plausible drivers from activity and market events you load, and keeps a reproducible trail for compliance-friendly reviews.
What FireAI tracks:
- Week-over-week and quarter trend by doctor and molecule
- Share of voice proxies where direct Rx is partial
- Correlation windows after detail or access change events
- Concentration of decline in accounts tied to specific stockists
Brand and sales leadership use doctor prescription trend inside pharma sales analytics to prioritize medical education, access work, and trade fixes with timing that matches the data.
Causal chain: Rx slip
New product adoption by territory
New product adoption pharma decays when launch KPIs stop at primary dispatch and never tie to early writers, repeat prescriptions, or chemist stocking. Territories that push samples without conversion look busy while high-potential patches with slow trial never get extra support.
FireAI tracks launch cohorts by territory with trialist counts, repeat rates, and linkage to coverage and stockist availability where data connects. New product adoption pharma ranks patches on adoption velocity versus fair peer benchmarks, not only absolute numbers.
How FireAI solves the problem: It aligns launch phase dates to CRM activities, flags territories where adoption lags despite adequate coverage, and highlights stockist or cold-chain constraints that masquerade as weak detailing.
What FireAI tracks:
- Trialists and repeat prescribers by patch and week
- Adoption index versus benchmark for similar launches
- MR coverage on targeted high-adopter segments
- Stockist service and returns on new SKUs
Brand and national sales use new product adoption pharma inside pharma sales analytics to move flex budget and medical resources before the launch window closes.